SCHEMBL25562018

SCHEMBL25562018

CN1CCN(C2CCN(c3ccc(Nc4nc(NC5CCOCC5)c(-c5ccccc5N)nc4C(N)=O)cc3)CC2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 17/20 0.75
ROS1 P08922 17/20 0.75
FLT3 P36888 17/20 0.75
EML4 Q9HC35 12/20 0.75
ALK Q9UM73 12/20 0.75
AXL P30530 2/20 0.62
ETV6 P41212 2/20 0.62
BMPR1B O00238 1/20 0.62
PLK4 O00444 1/20 0.62
CIT O14578 1/20 0.62
AURKA O14965 1/20 0.62
GAK O14976 1/20 0.62
EPHB6 O15197 1/20 0.62
RIPK2 O43353 1/20 0.62
BUB1 O43683 1/20 0.62
SNRNP200 O75643 1/20 0.62
STK16 O75716 1/20 0.62
STK10 O94804 1/20 0.62
MAP4K4 O95819 1/20 0.62
LATS1 O95835 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25561959 0.92 RET (0.74) RETROS1FLT3EML4ALK
SCHEMBL25562853 0.92 RET (0.74) RETROS1FLT3EML4ALK
SCHEMBL25562019 0.92 RET (0.74) RETROS1FLT3EML4ALK
SCHEMBL25561960 0.92 RET (0.73) RETROS1FLT3EML4ALK
SCHEMBL25561983 0.91 RET (0.73) RETROS1FLT3EML4ALK
SCHEMBL25561929 0.91 FLT3 (0.72) RETROS1FLT3EML4ALK
SCHEMBL25562803 0.91 RET (0.76) RETROS1FLT3EML4ALK
SCHEMBL25561969 0.90 RET (0.73) RETROS1FLT3EML4ALK
SCHEMBL25561988 0.90 RET (0.71) RETROS1FLT3EML4ALK
SCHEMBL28684203 0.90 RET (0.70) RETROS1FLT3EML4ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167099-A1 NEW PYRAZINE COMPOUND Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-06-01 US disclosed
US-20230167099-A1 NEW PYRAZINE COMPOUND Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167099-A1 NEW PYRAZINE COMPOUND EGFR, ERBB2, WEE1 RET 22/4885ROS1 31/4885FLT3 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.